An MDR1 promoter allele with higher promoter activity is common in clinically isolated strains of Candida albicans

Molecular Genetics and Genomics

Volumn 286, Issue 5-6, 2011, Pages 347-357

  Bruzual, Igor ^a,b   Kumamoto, Carol A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Candida albicans; Drug resistance; Fluconazole; MDR1; Polymorphism; Promoter

Indexed keywords

ALLELE; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; MULTIDRUG RESISTANCE PROTEIN 1 GENE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS;

CANDIDA ALBICANS;

EID: 85027947032     PISSN: 16174615     EISSN: 16174623     Source Type: Journal    
DOI: 10.1007/s00438-011-0650-z     Document Type: Article

References (64)

1. Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43(4):285-318 (Pubitemid 41030457)
2. Anderson JB (2005) Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness. Nat Rev Microbiol 3(7):547-556. doi:10.1038/nrmicro1179 (Pubitemid 40903878)
3. Barchiesi F, Colombo AL, McGough DA, Rinaldi MG (1994) Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol 32(10):2494-2500 (Pubitemid 24284652)
4. Bruzual I, Riggle P, Hadley S, Kumamoto CA (2007) Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole. J Antimicrob Chemother 59(3):441-450. doi:10.1093/jac/dkl521 (Pubitemid 47073449)
5. Chakrabarti A, Chatterjee SS, Rao KL, Zameer MM, Shivaprakash MR, Singhi S, Singh R, Varma SC (2009) Recent experience with fungaemia: Change in species distribution and azole resistance. Scand J Infect Dis 41(4):275-284. doi:10.1080/ 00365540902777105
6. Chalmers CM, Bal AM (2011) Management of fungal infections in the intensive care unit: A survey of UK practice. Br J Anaesth 106(6):827-831. doi:10.1093/bja/aer089
7. Cheng S, Clancy CJ, Nguyen KT, Clapp W, Nguyen MH (2007) A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother 51(5):1855-1858. doi:10.1128/AAC. 00182-07 (Pubitemid 46744173)
8. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D (2004) TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 3(6):1639-1652. doi:10.1128/EC.3.6.1639-1652.2004 (Pubitemid 40025121)
9. Coste A, Turner V, Ischer F, Morschhauser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D (2006) A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172(4):2139-2156. doi: 10.1534/genetics.105.054767
10. Defever KS, Whelan WL, Rogers AL, Beneke ES, Veselenak JM, Soll DR (1982) Candida albicans resistance to 5-fluorocytosine: Frequency of partially resistant strains among clinical isolates. Antimicrob Agents Chemother 22(5):810-815 (Pubitemid 13210059)
11. Denning DW, Hope WW (2010) Therapy for fungal diseases: Opportunities and priorities. Trends Microbiol 18(5):195-204. doi:10.1016/j.tim.2010.02.004
12. Dunkel N, Blass J, Rogers PD, Morschhauser J (2008) Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol 69(4):827-840. doi:10.1111/j.1365-2958.2008.06309.x (Pubitemid 352033303)
13. Fling ME, Kopf J, Tamarkin A, Gorman JA, Smith HA, Koltin Y (1991) Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 227(2):318-329
14. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J (1998) Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 42(12):3065-3072 (Pubitemid 28553719)
15. Gillum AM, Tsay EY, Kirsch DR (1984) Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198(1):179-182 (Pubitemid 15180998)
16. Gomez-Raja J, Andaluz E, Magee B, Calderone R, Larriba G (2008) A single SNP, G929T (Gly310Val), determines the presence of a functional and a non-functional allele of HIS4 in Candida albicans SC5314: Detection of the non-functional allele in laboratory strains. Fungal Genet Biol 45(4):527-541. doi: 10.1016/j.fgb.2007.08.008 (Pubitemid 351296469)
17. Goshorn AK, Scherer S (1989) Genetic analysis of prototrophic natural variants of Candida albicans. Genetics 123(4):667-673 (Pubitemid 20011812)
18. Graybill JR (1989) New antifungal agents. Eur J Clin Microbiol Infect Dis 8(5):402-412 (Pubitemid 19142008)
19. Gupta V, Kohli A, Krishnamurthy S, Puri N, Aalamgeer SA, Panwar S, Prasad R (1998) Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation. Curr Genet 34(3):192-199 (Pubitemid 28458486)
20. Harry JB, Oliver BG, Song JL, Silver PM, Little JT, Choiniere J, White TC (2005) Drug-induced regulation of the MDR1 promoter in Candida albicans. Antimicrob Agents Chemother 49(7):2785-2792. doi:10.1128/AAC.49.7.2785-2792.2005 (Pubitemid 40917592)
21. Hiller D, Stahl S, Morschhauser J (2006) Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazoleresistant clinical Candida albicans isolate. Antimicrob Agents Chemother 50(7):2300-2308. doi:10.1128/AAC.00196-06 (Pubitemid 43993166)
22. Hull CM, Raisner RM, Johnson AD (2000) Evidence for mating of the "asexual" yeast Candida albicans in a mammalian host. Science 289(5477):307-310. pii: 8669 (Pubitemid 30469910)
23. Jones T, Federspiel NA, Chibana H, Dungan J, Kalman S, Magee BB, Newport G, Thorstenson YR, Agabian N, Magee PT, Davis RW, Scherer S (2004) The diploid genome sequence of Candida albicans. Proc Natl Acad Sci USA 101(19):7329-7334. doi: 10.1073/pnas.0401648101 (Pubitemid 38638032)
24. Kelly R, Miller SM, Kurtz MB, Kirsch DR (1987) Directed mutagenesis in Candida albicans: One-step gene disruption to isolate ura3 mutants. Mol Cell Biol 7(1):199-208 (Pubitemid 17230400)
25. Kowalsky SF, Dixon DM (1991) Fluconazole: A new antifungal agent. Clin Pharm 10(3):179-194
26. Krishnamurthy S, Gupta V, Snehlata P, Prasad R (1998) Characterisation of human steroid hormone transport mediated by Cdr1p, a multidrug transporter of Candida albicans, belonging to the ATP binding cassette super family. FEMS Microbiol Lett 158(1): 69-74. pii: S0378-1097(97)00502-8 (Pubitemid 28088104)
27. Larsen RA (1990) Azoles and AIDS. J Infect Dis 162(3):727-730 (Pubitemid 20266167)
28. Lockhart SR, Daniels KJ, Zhao R, Wessels D, Soll DR (2003) Cell biology of mating in Candida albicans. Eukaryot Cell 2(1):49-61 (Pubitemid 36770375)
29. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF (1998) Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 42(11):2932-2937 (Pubitemid 28501228)
30. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF (1999) Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 43(7):1621-1630 (Pubitemid 29331238)
31. Lyons CN, White TC (2000) Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother 44(9):2296-2303 (Pubitemid 30650871)
32. Magee BB, Magee PT (2000) Induction of mating in Candida albicans by construction of MTLa and MTLalpha strains. Science 289(5477):310-313. pii: 8662 (Pubitemid 30469911)
33. Mogavero S, Tavanti A, Senesi S, Rogers PD, Morschhauser J (2011) Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob Agents Chemother 55(5):2061-2066. doi:10.1128/AAC.01467-10
34. Morschhauser J (2002) The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587(2-3):240-248. pii: S092544390200087X (Pubitemid 34655792)
35. Morschhauser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47(2):94-106. doi:10.1016/j.fgb. 2009.08.002
36. Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R and Rogers PD (2007). The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 3(11): E164. doi: 10.1371/journal.ppat.0030164 (Pubitemid 350291598)
37. Nucci M, Anaissie E (2001) Revisiting the source of candidemia: Skin or gut? Clin Infect Dis 33(12):1959-1967. doi:10.1086/323759 (Pubitemid 33152388)
38. Odds FC (1987) Candida infections: An overview. Crit Rev Microbiol 15(1):1-5. doi:10.3109/10408418709104444
39. Odds FC, Hierholzer JC (1973) Purification and properties of a glycoprotein acid phosphatase from Candida albicans. J Bacteriol 114(1):257-266
40. Pienaar ED, Young T and Holmes H (2010). Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev(11): CD003940. doi:10.1002/14651858. CD003940.pub3
41. Pinjon E, Moran GP, Coleman DC, Sullivan DJ (2005) Azole susceptibility and resistance in Candida dubliniensis. Biochem Soc Trans 33(Pt 5):1210-1214. doi:10.1042/BST20051210 (Pubitemid 41659151)
42. Provine H, Hadley S (2000) Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds. J Clin Microbiol 38(2):537-541 (Pubitemid 30082637)
43. Riggle PJ, Kumamoto CA (2006) Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazoleresistant Candida albicans strains through an Mcm1p binding site. Eukaryot Cell 5(12):1957-1968. doi:10.1128/EC.00243-06 (Pubitemid 44956808)
44. Rognon B, Kozovska Z, Coste AT, Pardini G, Sanglard D (2006) Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 152(Pt 12):3701-3722. doi:10.1099/mic.0.29277-0 (Pubitemid 46040691)
45. Rose MD, Winston F, Hieter P (1990) Methods in yeast genetics: A laboratory course manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
46. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M (1994) Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 32(9):2092-2098 (Pubitemid 24258446)
47. Sanglard D, Ischer F, Monod M, Bille J (1997) Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(Pt 2):405-416 (Pubitemid 27092176)
48. Sanglard D, Coste A, Ferrari S (2009) Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 9(7):1029-1050. doi:10.1111/j.1567-1364.2009.00578.x
49. Sanz M, Valle R, Roncero C (2007) Promoter heterozygosity at the Candida albicans CHS7 gene is translated into differential expression between alleles. FEMS Yeast Res 7(6):993-1003. doi:10.1111/j.1567-1364.2007.00264.x (Pubitemid 47256368)
50. Schubert S, Rogers PD, Morschhauser J (2008) Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazoleresistant Candida dubliniensis strains. Antimicrob Agents Chemother 52(12):4274-4280. doi:10.1128/AAC.00740-08
51. Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aid M, Boucher G, Rogers PD, Raymond M, Morschhauser J (2011) Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother 55(5):2212-2223. doi: 10.1128/AAC.01343-10
52. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J (2008) An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68(3): 624-641. doi:10.1111/j.1365-2958.2008. 06176.x (Pubitemid 351490182)
53. Selmecki AM, Dulmage K, Cowen LE, Anderson JB and Berman J (2009). Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 5(10): E1000705. doi:10.1371/journal. pgen.1000705
54. Slutsky B, Buffo J, Soll DR (1985) High-frequency switching of colony morphology in Candida albicans. Science 230(4726): 666-669 (Pubitemid 16190959)
55. Staib P, Kretschmar M, Nichterlein T, Hof H, Morschhauser J (2002) Host versus in vitro signals and intrastrain allelic differences in the expression of a Candida albicans virulence gene. Mol Microbiol 44(5):1351-1366. pii: 2967 (Pubitemid 34595765)
56. Vogel M, Hartmann T, Koberle M, Treiber M, Autenrieth IB, Schumacher UK (2008) Rifampicin induces MDR1 expression in Candida albicans. J Antimicrob Chemother 61(3):541-547. doi: 10.1093/jac/dkm513 (Pubitemid 351321125)
57. Whelan WL, Magee PT (1981) Natural heterozygosity in Candida albicans. J Bacteriol 145(2):896-903 (Pubitemid 11140421)
58. Whelan WL, Soll DR (1982) Mitotic recombination in Candida albicans: Recessive lethal alleles linked to a gene required for methionine biosynthesis. Mol Gen Genet 187(3):477-485 (Pubitemid 13218799)
59. Whelan WL, Partridge RM, Magee PT (1980) Heterozygosity and segregation in Candida albicans. Mol Gen Genet 180(1):107-113 (Pubitemid 11212159)
60. White TC (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41(7):1482-1487 (Pubitemid 27289672)
61. White TC, Holleman S, Dy F, Mirels LF, Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46(6):1704-1713 (Pubitemid 34535186)
62. White SJ, Rosenbach A, Lephart P, Nguyen D, Benjamin A, Tzipori S, Whiteway M, Mecsas J and Kumamoto CA (2007). Selfregulation of Candida albicans population size during GI colonization. PLoS Pathog 3(12): E184. doi:10.1371/journal. ppat.0030184
63. Wirsching S, Michel S, Kohler G, Morschhauser J (2000a) Activation of the multiple drug resistance gene MDR1 in fluconazoleresistant, clinical Candida albicans strains is caused by mutations in a trans-regulatory factor. J Bacteriol 182(2):400-404 (Pubitemid 30030124)
64. Wirsching S, Michel S, Morschhauser J (2000b) Targeted gene disruption in Candida albicans wild-type strains: The role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 36(4):856-865. pii: Mmi1899 (Pubitemid 30326531)